PT  - JOURNAL ARTICLE
AU  - Nagano, Katsutoshi
AU  - Tani-Sassa, Chihiro
AU  - Iwasaki, Yumi
AU  - Takatsuki, Yuna
AU  - Yuasa, Sonoka
AU  - Takahashi, Yuta
AU  - Nakajima, Jun
AU  - Sonobe, Kazunari
AU  - Ichimura, Naoya
AU  - Nukui, Yoko
AU  - Takeuchi, Hiroaki
AU  - Tanimoto, Kousuke
AU  - Tanaka, Yukie
AU  - Kimura, Akinori
AU  - Tohda, Shuji
TI  - SARS-CoV-2 R.1 lineage variants prevailed in Tokyo in March 2021
AID  - 10.1101/2021.05.11.21257004
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.11.21257004
4099  - http://medrxiv.org/content/early/2021/05/20/2021.05.11.21257004.short
4100  - http://medrxiv.org/content/early/2021/05/20/2021.05.11.21257004.full
AB  - Background The spread of SARS-CoV-2 variants, such as B.1.1.7 and B.1.351, has become a crucial issue worldwide. Therefore, we began testing all patients with COVID-19 for the N501Y and E484K mutations by using polymerase chain reaction (PCR)-based methods.Methods Nasopharyngeal swab samples from 108 patients who visited our hospital between February and April 2021 were analyzed. The samples were analyzed using reverse transcription-PCR with melting curve analysis to detect the N501Y and E484K mutations. A part of the samples were also subjected to whole genome sequencing (WGS). Clinical parameters such as mortality and admission to the intensive care unit were analyzed to examine the association between increased disease severity and the E484K mutation.Results The ratio of cases showing the 501N+484K mutation rapidly increased from 8% in February to 46% in March. WGS revealed that the viruses with 501N+484K mutation are R.1 lineage variants. Evidence of increased disease severity related to the R.1 variants were not found.Conclusions We found that the R.1 lineage variants rapidly prevailed in Tokyo in March 2021, which suggests the increased transmissibility of R.1 variants while they showed no increased severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWGS was supported by: grant JPMJCR20H2 from JST-CREST; grant 20nk0101612h0901 from Japan Agency for Medical Research and Development.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Medical Research Ethics Committee of Tokyo Medical and Dental University (approval number: M2020-004) .All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will provide the PCR protocol and data on request.